HILOPRO

®

Viscosity Reduction technology for Monoclonal Antibodies

Concentrations higher than 225mg/mL

Viscosity lower than 20cP

Upgrade your mAbs from IV to SubQ

The Qprotyn patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance. 

shutterstock_1084683527.jpg

HILOPRO    Technology

TM

Upgrade your mAb from IV to SUBQ.

 

Re-imagine your biologic API delivered subcutaneously in a single dose up to 375mg in a 1.5mL syringe.

Proof of Concept with your mAb in
8 Weeks !

Active Senior Man

Contact Us

Thank you! We will get back to you shortly.